3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Completed
5
Recruiting
3
Terminated
2
Unknown
1
Active not recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
2
Conditions
Colorectal Neoplasms
5
Pancreatic Neoplasms
2
Neoplasm Metastasis
2
Spinocerebellar Degenerations
1
Small Cell Lung Carcinoma
1
Neuroendocrine Tumors
1
Neuroectodermal Tumors, Primitive
1
Neoplasms
1
High-grade Extra Pulmonary Neuroendocrine Cancer
1
Cholangiocarcinoma
1
Bile Duct Neoplasms
1
Adenocarcinoma
1
Interventions
pembrolizumab
30
Capecitabine
24
Bevacizumab
23
Cyclophosphamide
22
Gemcitabine
21
Paclitaxel
20
Nivolumab
19
Fluorouracil
19
Docetaxel
18
aldesleukin
17
Leucovorin
17
Irinotecan
17
Oxaliplatin
15
Interleukin-2
14
Radiosurgery
13
Cisplatin
13
Cetuximab
13
fludarabine
12
Carboplatin
12
Albumin-Bound Paclitaxel
11
fludarabine phosphate
10
Ipilimumab
10
Drug Therapy
10
Doxorubicin
10
Sunitinib
9
Radiotherapy
9
Everolimus
9
130-nm albumin-bound paclitaxel
9
Trastuzumab
8
Temozolomide
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Terminated
×
Neoplasm Metastasis
×
trifluridine tipiracil drug combination
×
Clear all
NCT05223673
2024-08-20
COLSTAR
Servier
Phase 3
Terminated
7 enrolled
12 charts
NCT02921737
2021-02-04
UF-STO-PANC-003
University of Florida
Phase 2
Terminated
7 enrolled
12 charts